




The Department of Health and Human Services

REPORT TO CONGRESS

Pandemic Influenza Preparedness Spending

Prepared in Response to Request in
Conference Report 109-359

 DATE June 29, 2007

Charles E. Johnson
Assistant Secretary for Resources and Technology
June 2007

Report Language – Conference Report 109-359

“The conferees direct the Secretary to provide on a semi-annual basis to the House and Senate Appropriations Committees a report identifying the disbursements of funds received under this heading and a listing of the governments, companies and organizations that received funding. The report should include the amount and purpose of each grant or other form of assistance. Finally, the report should include the cumulative obligations by activity of the funds made available under this heading for pandemic preparedness, as well as any remaining unobligated balances.”

AND

“The conferees direct the Secretary of Health and Human Services to provide the Committees on Appropriations with quarterly reports on the expenditure of the funds provided for the Food and Drug Administration in this Act for pandemic influenza preparedness. The reports shall also include details on any reimbursements received by the agency from any other federal agencies for expenses incurred for pandemic influenza preparedness. The first report shall be transmitted no later than February 15, 2006.”

Introduction

This report is an update to the previous reports to Congress that were provided in June and December 2006. This report covers all activities from December 2005 to June 2007. The report covers both the December 2005 emergency supplemental (PL 109-148) and the June 2006 emergency supplemental (PL 109-234).

In August 2005, animal outbreaks of highly pathogenic H5N1 had been reported in twelve countries around the world with 112 total human cases confirmed in four of those countries. Almost two years later in June 2007, the number of countries confirming animal outbreaks has jumped to 60, with 309 total human cases confirmed in twelve of those countries. While the majority of human cases to date can be attributed to exposure to infected poultry, the human infections have been severe. Overall, 61 percent of human cases have been fatal. Once a pandemic begins, time will be a critical factor in our ability to accomplish the necessary production and delivery of vaccines and other medical countermeasures required to mitigate the pandemic.

On November 1, 2005, the President requested a total of \$7.1 billion in emergency funding for pandemic influenza preparedness activities, of which \$6.7 billion was for implementation of the *HHS Pandemic Influenza Plan*. This funding was requested in FY 2006 to fund a three-year preparedness effort to ensure the Nation could effectively respond in the event of a pandemic. In December 2005, Congress appropriated \$3.3 billion in emergency funding for HHS in a FY 2006 supplemental, for the first year of the *HHS Pandemic Influenza Plan*. In June 2006, Congress appropriated \$2.3 billion for HHS in emergency funding in a second FY 2006 supplemental for the second year of the HHS Plan. In addition, HHS has requested \$870 million in the FY 2008 President’s Budget in one-time funding to continue these efforts. Since December 2005, HHS has been funding the first stage of pandemic preparedness activities, which include: expanding

and diversifying domestic vaccine production and surge capacity; enlarging H5N1 pre-pandemic vaccine and antiviral drug stockpiles; supporting advanced development of cell culture and antigen sparing influenza vaccines, and new antiviral drugs; advanced development of point-of-care clinical diagnostics; stockpiling of medical supplies and ventilators; improving State and local preparedness; expanding risk communication efforts; enhancing FDA’s regulatory science base; and expanding surveillance, research, and international collaboration efforts of CDC, NIH, and the HHS Office of Global Health Affairs.

HHS has made tremendous strides in enhancing pandemic preparedness for our Nation and our international partners. Today we are more prepared than we were in December 2005, the month the first emergency supplemental was appropriated. As of June 2007, HHS has obligated approximately \$3.0 billion in pandemic influenza funds and has unobligated balances totaling \$2.6 billion from the two emergency supplemental appropriations bills. HHS has already made commitments for the use of these funds or has plans to obligate the funds by the end of FY 2007/early FY 2008. This report highlights key accomplishments on our path to pandemic preparedness and details how appropriated funds have been spent to date.

This report only highlights funds that have been obligated. However, in several of the advanced development contracts, milestones must be achieved for awarding additional funding in FY 2007/FY 2008. One example is the advanced development of a cell-based pandemic influenza vaccine, in which the contractor must demonstrate adequate product safety and efficacy in Phase 2 clinical studies and appropriate domestic manufacturing facility biosecurity. Another example is the advanced development of an antigen-sparing pandemic influenza vaccine, in which successful completion of phase 1 trials of the candidate vaccine must be obtained. In addition, the remaining State and local preparedness funds will be released this fiscal year, in conjunction with the annual bioterrorism preparedness cooperative agreements. The funds for the annual preparedness cooperative agreements are released at the end of each fiscal year.

The currently planned allocations of funding by category included in the table below and in this report are based on the best scientific evidence and technical information available. HHS may reallocate these funds in the future should new scientific or technological opportunities or contracting realities necessitate modification in order to best advance our Nation’s pandemic response capabilities. Pandemic influenza funding has also been used to support administrative expenses necessary to achieve the goals of the *HHS Pandemic Influenza Plan*.

FY 2006 Pandemic Influenza Supplemental Funding			
<i>(dollars in millions)</i>			
	December 2005	June 2006	Total
Vaccines.....	1,781	1,452	3,233
Antivirals.....	731	350	1,081
Medical Supplies.....	162	8	170
State and Local Preparedness.....	350	250	600
International Collaboration.....	125	54	179
Other Domestic Activities.....	138	138	276
Risk Communications.....	33	18	51
Total, HHS.....	3,320	2,270	5,590

Vaccine

A key goal of the *HHS Pandemic Influenza Plan* is to provide pandemic influenza vaccine to every American within six months of detection of sustained human-to-human transmission of pandemic influenza. To achieve this goal, HHS is investing in the expansion of vaccine manufacturing capacity (egg- and cell-based), the advanced development of new cell-based vaccines, antigen-sparing technologies, and the establishment and maintenance of pre-pandemic vaccine stockpiles.

Accomplishments to Date:

- In June 2007, HHS awarded \$132.5 million to sanofi pasteur and MedImmune for the retrofitting of existing domestic manufacturing facilities of U.S.-licensed biologicals for pandemic influenza vaccine production to increase domestic egg-based and other influenza vaccine production capacity and for warm base manufacturing operations through new and converted facilities.
- In January 2007, HHS awarded three contracts totaling \$132.5 million to GlaxoSmithKline, Novartis and IOMAI for the advanced development of H5N1 influenza vaccines using antigen-sparing techniques toward U.S. licensure and expanded domestic vaccine manufacturing surge capacity. One contract may receive additional funding based upon successful completion of phase 1 trials in 2007 of a candidate vaccine.
- In May 2006, HHS awarded five contracts for over \$1 billion to GlaxoSmithKline, MedImmune, Novartis (formerly Chiron), Solvay, and Dynport (with Baxter) for support of advanced development of cell-based influenza vaccines toward U.S. licensure and expanded domestic vaccine manufacturing surge capacity. These contracts may afford U.S. production of at least 240 million courses of cell-based pandemic vaccine within six months of the emergence of a pandemic influenza virus. HHS expects to issue a Request for Proposals (RFP) for the advanced development of next generation recombinant influenza vaccines that may shorten the timeline for production and release of pandemic influenza vaccine.
- HHS allocated \$180 million from the supplemental in Fall 2005 to purchase approximately 2.7 million courses of H5N1 clade 1 bulk vaccine from sanofi Pasteur and Novartis (formerly Chiron). With funding from the December 2005 supplemental, HHS awarded three contracts for \$207 million in November 2006 to procure 3.7 million vaccine courses of H5N1 clade 1 and 2 bulk vaccine from sanofi pasteur, Novartis, and GlaxoSmithKline. Recognizing that the H5N1 virus continues to evolve, this purchase included both clade 1 and clade 2 vaccine. The term “clade” refers to the genetic variants (antigenic drift) of an influenza virus strain. Additional task orders for H5N1 bulk vaccine will be issued in 2007 using these contracts to take full advantage of the limited manufacturing windows using the currently circulating H5N1 influenza virus.

As of June 15, 2007, HHS has obligated \$1.5 billion out of the \$3.2 billion allocated between the two supplementals for vaccine-related activities. Commitments for remaining funds include:

- HHS plans to purchase additional doses of H5N1 vaccine for pre-pandemic influenza vaccine national stockpile in summer of 2007 off existing contracts.
- HHS is considering additional funding in the summer of 2007 to one of the cell-based influenza vaccine contractors for further clinical investigational lots manufacturing and late stage clinical studies depending on results of biocontainment and security analysis of domestic vaccine manufacturing facility plans.
- HHS is considering additional funding in late 2007 to a contractor for the advanced development of antigen-sparing techniques for further investigational lots manufacturing and late stage clinical studies depending on the results of the Phase 1 trials. These funds could be obligated quickly if the manufacturer meets its milestones.

Antivirals

Another key goal in the *HHS Pandemic Influenza Plan* is to ensure the availability of antiviral treatment courses for 25 percent of the U.S. population. The Federal government and States will accomplish this goal by together purchasing a total of 81 million courses of antivirals.

To accomplish the Federal portion of this goal by the end of FY 2008, the Federal government will complete the 50 million course antiviral stockpile purchase for the Strategic National Stockpile. The majority of that stockpile, 44 million courses, will be allocated based on population to the 62 Public Health Emergency Preparedness Project Areas. In addition, the Federal government has stockpiled six million treatment courses to attempt to mitigate localized outbreaks of pandemic influenza, bringing the Federal stockpile total to 50 million treatment courses. As of June 15, 2007, HHS has approximately 37 million courses of antivirals on hand and/or on order.

In addition, almost all States have taken advantage of a Federal contracting subsidy that allows States to purchase a total of 31 million treatment courses of antivirals by leveraging Federal “best price” contracts and a subsidy of up to 25 percent of the Federal contract price. States also purchased antivirals using these Federal contracts with unsubsidized funds, allowing them to purchase additional doses beyond what was initially projected.

Accomplishments to Date:

- As of June 15, 2007, HHS has ordered over 37 million courses of Tamiflu and Relenza, of which approximately 36 million treatment courses have been delivered to the Strategic National Stockpile (SNS) and the remaining 1 million are due for delivery by July 2007.
- In January 2007, HHS awarded a contract for \$102 million for the advanced development of a new neuraminidase-inhibitor class of influenza antiviral drugs that may be used parenterally for life-threatening cases of severe or pandemic influenza in hospitals.
- Federal contracts for States to use for the purchase of Federally-subsidized and unsubsidized purchases of influenza antiviral drugs were awarded to Roche for Tamiflu and GSK for

Relenza in summer of 2006. States have indicated to HHS that they will purchase approximately 30 million treatment courses of antivirals with subsidized funding. States are currently placing orders for these treatment courses with manufacturers using Federal contracts at discounted prices. To date the States have purchased 13.6 million treatment courses of these influenza antiviral drugs for pandemic stockpiles, of which 12.4 million treatment courses have been delivered. Commitments from all States have been received to utilize the Federal subsidy allocations to purchase at least 31 million treatment courses by July 2008.

As of June 15, 2007, HHS has obligated \$660 million out of the \$1.1 billion allocated between the two supplementals for antiviral-related activities. HHS has expended all funds allocated for direct Federal stockpile of antivirals. HHS expects to issue an RFP in 2008 for the advanced development of more new influenza antiviral drugs including combination therapeutics to circumvent development of drug resistance and drugs with different viral and host targets.

Medical Supplies

HHS is expanding medical infrastructure and response capacity during an influenza pandemic by stockpiling medical supplies for distribution to States in the event of a pandemic. HHS' plan is to purchase personal protective equipment (e.g., surgical masks and respirators) to help reduce exposure to the pandemic influenza virus and thereby reduce the spread of the disease. In addition, HHS plans to purchase and stockpile ventilators to provide assistance in patient breathing to the critically ill. Other purchases include intravenous antibiotics, syringes and needles, and non-pharmaceuticals.

Accomplishments to Date:

- HHS has purchased approximately 156 million masks and respirators, for approximately \$50 million. This includes 105 million N95 respirators and 52 million surgical masks.
- HHS has obligated \$100 million for the purchase of ventilators, syringes, and IV antibiotics for potential distribution to affected areas in case of an influenza pandemic.

As of June 15, 2007, HHS has obligated \$157 million out of the \$170 million allocated between the two supplementals for medical supplies.

State and Local Preparedness

A pandemic will be widespread and will affect many areas of the country simultaneously. Thus, States and local governments will play a critical role in responding to a pandemic. HHS has been working with State and local communities to update their pandemic influenza plans and to ensure that they evaluate their plans through exercises. States have submitted their current pandemic influenza plans to CDC. HHS has also provided States additional information on exercise requirements related to mass vaccination and non-pharmaceutical interventions and distribution of antiviral drugs and other countermeasures, specifically school closures. HHS has conducted a pandemic influenza summit in every State and Territory. These summits brought

together HHS leadership with State leadership, health professionals, schools, and the private sector to discuss State and community preparedness issues.

Accomplishments to Date:

- In 2006, HHS awarded a total of \$325 million for State and local preparedness and conducted over 50 State pandemic influenza summits. The remaining \$25 million from the \$350 million appropriated for State and local preparedness in the December 2005 supplemental will be awarded to States on a competitive basis this fiscal year.
- An additional \$250 million was appropriated for State and local preparedness in the June 2006 emergency supplemental. These remaining State and local preparedness funds will be released this fiscal year, in conjunction with the annual bioterrorism preparedness cooperative agreements. The funds for the annual preparedness cooperative agreements are released at the end of each fiscal year.
- HHS has partnered with the National Governors Association (NGA) to assist States in upgrading their pandemic influenza preparedness capabilities. In advance of participation in regional exercises, NGA is assisting States in updating plans according to current HHS guidance. NGA is holding up to 10 meetings that focus on State pandemic preparedness using table-top exercises to test intergovernmental and interstate coordination. NGA is assisting States in updating plans to address gaps and new benchmarks identified through the regional exercises. Finally, NGA is in the process of developing a best practices summary of State pandemic influenza preparedness activities.

As of June 15, 2007, HHS has obligated \$326 million out of the \$600 million available between the two supplementals for State and local preparedness. HHS will obligate the remainder of these funds this fiscal year.

International Collaboration

HHS is actively engaged with countries around the world to help them prepare for the possibility of a pandemic influenza outbreak, and to help minimize and contain the impact of an outbreak should one occur. HHS is collaborating with the U.S. Departments of State and Agriculture, as well as the U.S. Agency for International Development to enhance preparedness in other countries by providing training, direct assistance, supplies, reagents and technical support to the World Health Organization, Ministries of Health (MOH) and non-governmental organizations (NGOs). HHS is also actively engaged with the Department of Defense, through entities such as the U.S. Naval Medical Research Units.

Accomplishments to Date:

- Technical assistance to enhance preparedness and response includes laboratory workshops on molecular diagnosis of avian influenza, training workshops for rapid response teams (RRTs), and on-site participation in field investigations of human H5N1 cases, including analysis of disease clusters to determine whether third generation

transmission (human-to-human-to-human) is occurring. Ongoing consultation is provided by HHS/CDC Influenza Coordinators stationed in affected countries, in WHO Regional Offices, and in Global Disease Detection (GDD) Centers. The GDD Centers in Guatemala, Kenya and Thailand have fully equipped rapid response teams that can be deployed regionally, as well as stockpiles of personal protective equipment and antiviral medications for use during the initial wave of a pandemic.

- HHS continues to support activities and make investments in approximately 40 countries, and is implementing programs through regional platforms, direct assistance, and with international partners such as the World Health Organization (WHO), the Institut Pasteur, the International Center for Diarrheal Disease Research in Bangladesh, the REDI Center in Singapore, and the Gorgas Memorial Institute in Panama. The Department has placed dedicated influenza experts in priority countries, WHO headquarters and its regional offices, as well as at the European Centre for Disease Control.
- With pandemic funds provided by HHS, the WHO Secretariat has conducted a number of workshops worldwide for country representatives involved with communicating key health information prior to and during an influenza pandemic. Representatives from about 70 countries have participated in at least four large international workshops to train trainers, to educate journalists on outbreak communications, and to take part in “table top” outbreak simulations that focused on developing communications activities to help serve public health objectives.
- HHS supports a new Field Epidemiology and Laboratory Training Program (FELTP) in South Africa and is helping to establish additional FELTPs in Nigeria and West Africa. The FELTPs are two-year, full-time applied public health training programs with approximately 25 percent classroom training and 75 percent on-the-job training through field placements providing epidemiologic service to Ministries of Health. FELTPs yield long-term, sustained results by reinforcing a culture of evidence-based practice and providing competent, motivated public health professionals able to respond to a multitude of public health threats.
- As of May 2007, HHS/CDC has 21 infectious disease consultants stationed overseas including 5 CDC Influenza Coordinators stationed at GDD Centers in China, Egypt, Guatemala, Kenya, Thailand, and 16 CDC staff responsible for influenza activities in Cambodia, Republic of the Congo, Egypt, India, Indonesia, Kazakhstan, Laos, Peru, Philippines, Sweden, Switzerland, Vietnam, and the United Kingdom.
- U.S. Naval Medical Research Unit No. 3 (NAMRU-3) has an Interagency Agreement (IAA) with HHS/CDC to provide technical assistance with influenza diagnostics and surveillance to: Afghanistan, Armenia, Azerbaijan, Bulgaria, Macedonia, Morocco, Romania, Ukraine and Uzbekistan. NAMRU-3 also provides influenza support to WHO/EMRO countries (including Djibouti, Egypt, Jordan, Oman, Pakistan, Saudi Arabia and Syria) and to Georgia, Kazakhstan, and Kyrgyzstan. NAMRU-3 also assists NAMRU-K in collaboration with the CDC GDD Center in Nairobi, in conducting

influenza surveillance in Kenya. Beginning in late 2007, NAMRU-3 may also provide assistance to Tajikistan and Turkmenistan.

- HHS funds the WHO Secretariat to support the development of influenza vaccine production capability in developing countries. Over the last six months, the WHO solicited proposals from developing countries, conducted a comprehensive review, and has recently awarded contracts to vaccine manufacturing sites in six different countries (Vietnam, Thailand, India, Indonesia, Mexico, and Brazil), to help them add the production equipment, technology and technical expertise needed to manufacture influenza vaccines in the event of a pandemic.
- The National Institutes of Health National Institute of Allergy and Infectious Diseases (NIH/NIAID) awarded a contract for \$8 million to expand the Southeast Asian Influenza Clinical Research Network, a collaborative partnership of hospitals and institutions in Indonesia, Thailand, the United Kingdom, the United States, and Vietnam. The funding will accelerate the establishment of additional clinical research sites whose mission is to advance the scientific knowledge and management of human influenza through research into the development of therapeutics, diagnostics and vaccines.

As of June 15, 2007, HHS has obligated \$129 million out of the \$179 million allocated between the two supplementals for international collaboration. The remaining \$50 million will be used to continue to carry out activities begun in FY 2006 through FY 2007.

Other Domestic Activities, including Risk Communications

HHS is working on the domestic front to enhance surveillance through partnerships with State and local laboratories. HHS is working to increase and expand the capacity of quarantine stations, enhance laboratory capacity at the CDC, and improve diagnostic tools. The development of rapid diagnostics will facilitate the speed and accuracy with which scarce countermeasures will be distributed. Risk communication strategies are being developed and implemented. These activities will allow HHS to build the domestic capacity needed to detect and respond to a pandemic early and effectively.

Accomplishments to Date:

- In November 2006, HHS awarded contracts totaling \$11.4 million to four companies working to develop new diagnostic tests that doctors and field epidemiologists could eventually use to quickly and accurately test patients for avian influenza H5N1 and other emerging influenza viruses, as well as more common influenza viruses. The goal is to create a test that would detect seasonal human influenza viruses and differentiate influenza A H5N1 from seasonal human influenza viruses within 30 minutes, thus allowing for ideal distribution of vaccines, antivirals, and other scarce resources.
- In February 2007, HHS initiated a public education campaign designed to raise awareness of pandemic influenza and the steps individuals and families can take now to prepare as well as to create a foundation of pandemic awareness and knowledge to

support future response and recovery efforts. In addition to public service announcements, the campaign includes audience research, strategic planning, stakeholder outreach, special events, and media outreach.

- In early 2007, HHS sponsored table-top exercises with key media leaders and senior government officials, representing several Federal agencies, in New York, Chicago, Los Angeles, Miami, Washington, DC and Atlanta. The purpose of these exercises was to facilitate effective two-way communication between the media and senior government officials about the challenges of delivering timely and accurate information to the public during a pandemic. The discussion was intended to help both the media and government better plan for communicating during a pandemic.
- In January 2007, HHS initiated a series of public engagement meetings to examine public views and values with respect to pandemic vaccine prioritization. In January, public engagement meetings were held in Atlanta, GA and Las Cruces, NM. Additional public engagement and stakeholder meetings are planned.
- CDC is currently working on several activities to enhance surveillance for pandemic influenza. Over \$27 million was obligated to further investigate real-time data sources and other activities in BioSense. Approximately \$18 million was obligated on quarantine activities such as improving detection, surveillance and response for influenza.
- CDC has obligated over \$49 million to enhance and upgrade CDC's lab capacity, including purchasing essential lab equipment and hardware and software.

As of June 15, 2007, HHS has obligated \$151 million out of the \$332 million allocated between the two supplementals for these domestic activities.

FDA

FDA's efforts to enhance its infrastructure and provide personnel and expertise in the essential clinical, product and manufacturing areas are vital to support new vaccine development.

FDA has obligated \$19 million of the \$20 million in emergency supplemental funds on pandemic influenza activities. Accomplishments include:

- In May 2007, FDA issued guidance on the "Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines."
- In April 2007, FDA licensed the first vaccine for humans against the H5N1 influenza virus.
- Completed renovation of pandemic influenza virus research laboratory which will allow for enhanced research activities to facilitate the development and manufacture of pandemic influenza vaccines.

- Collaborated with academic experts from St. Jude Children's Research Hospital to create a potential pandemic vaccine candidate for A/dk/Laos/3295/06.
- As part of an effort to shorten vaccine production timelines, FDA initiated research studies to address feasibility of alternative methods for production of influenza vaccine potency reagents.
- Completed preparation of reference reagents for the H5N1 A/Indonesia/5/05 candidate vaccine that is used by manufacturers to determine the potency of their candidate pandemic vaccines.
- Developing regulatory pathways for the development of vaccines for use in the period prior to a pandemic, such as for priming the general population.
- Organized and convened a Vaccines and Related Biological Products Advisory Committee to discuss prime/boost strategies for new candidate pandemic influenza vaccines.
- Presented the first U.S. biologics license application for a vaccine against H5N1 influenza to the Vaccines and Related Biological Products Advisory Committee to obtain the committee's advice regarding safety and effectiveness. In addition to FDA, NIH, CDC and HHS also presented to the Committee. This was the first pre-pandemic vaccine licensed anywhere in the world.
- Continues to expeditiously review and provide advice on the development of many influenza vaccine candidates under investigational new drug application, including those manufactured with new adjuvants or grown in cell cultures or that utilize recombinant technologies.
- Initiated a collaborative study with Brooke Army Medical Center to investigate the correlates of immunity following immunization with live attenuated influenza vaccine and trivalent inactivated influenza vaccine by collecting pre- and post immunization sera.
- Initiated transfer of influenza vaccine testing to a new quality laboratory established within the Office of Vaccines Research and Review.
- FDA has established active liaison relationships with the major blood, plasma and tissue professional organizations to facilitate the preparation of strategic plans designed to sustain the supply and safety of labile biological products in the event of a pandemic. The organizations include the Department of Health and Human Services, Office of the Secretary and Public Health Science (HHS/OSP), the Centers for Disease Control and Prevention, as well as organizations outside government such as the American Association of Blood Banks (AABB) and its Disaster and Pandemic Influenza Task Forces. CBER staff led a Public Health Service (PHS)/HHS Pandemic Influenza working group that shares information and develops pandemic influenza preparations related to the blood supply. In addition, CBER leads a monthly PHS Blood meeting that includes pandemic planning as a regularly scheduled topic. To ensure effective, continuing operations for a pandemic influenza situation, we are developing our own internal Continuity of Operations plan.

FDA has considered the regulatory implications of a pandemic national environment and has designed pathways for emergency variances and other candidate regulatory responses to sustain local supplies of critical blood products should reductions of available blood donors and blood center staff result in severe disruptions to blood availability.

In mid-March 2007, FDA issued its Pandemic Influenza Preparedness Strategic Plan (Pandemic Strategic Plan). The plan was developed by the FDA Pandemic Influenza Preparedness Task Force (Task Force) under the leadership of the Office of the Commissioner through the Office of Counterterrorism Policy and Planning and the Office of Policy.

Department of Health and Human Services
Report to Congress
Pandemic Influenza
(\$ in millions)

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Vaccine Funding	1,781.0	1,452.0
ACHIEVE CAPACITY AND/OR BUY COURSES FROM EGG-BASED MANUFACTURER	511.0	300.0
ASPR -- Contract award (11/06) to Sanofi Pasteur Purpose - Contract issued for the acquisition of H5N1 (Clade 2) vaccine for pre-pandemic stockpile.	118.0	
ASPR -- Contract award (11/06) to Glaxo SmithKline Purpose - Contract issued for the acquisition of H5N1 (Clade 2) vaccine for pre-pandemic stockpile.	41.0	
ASPR -- Contract awarded (11/06) to Novartis Purpose - Contract issued for the acquisition of H5N1 (Clade 2) vaccine for pre-pandemic stockpile.	41.0	
ASPR -- Task Order on contract (#10020050004C) issued (9/22/06) to sanofi pasteur Purpose -Modification issued for storage and stability studies.	4.8	
ASPR -- Modification to Sanofi Pasteur contract (Achieve Capacity) 1/26/07 Purpose - Modification issued for the acquisition of H5N1 (Clade 2) vaccine for pre-pandemic stockpile	4.4	
ASPR/CDC -- Contracts awarded to Sanofi Pasteur and Chiron Purpose - Contract issued for the acquisition of H5N1 vaccine for pre-pandemic stockpile.	80.0	
Cumulative Obligations, Achieve Capacity and/or Buy Courses	289.2	0.0
<i>Unobligated Balances, Achieve Capacity and/or Buy Courses</i>	<i>221.8</i>	<i>300.0</i>
ACCELERATE CELL-BASED VACCINE	1,010.0	842.0
ASPR -- Contract awarded (5/1/06) to Glaxo SmithKline Purpose - Contract issued for the advanced develop. of cell-based pan flu vaccines for domestic licensure & mfg	223.0	
ASPR -- Contract (#10020060010C) awarded (5/1/06) to MedImmune Purpose - Contract issued for the advanced develop. of cell-based pan flu vaccines for domestic licensure & mfg	169.0	
ASPR -- Contract awarded (5/1/06) to Novartis/Chiron Purpose - Contract issued for the advanced develop. of cell-based pan flu vaccines for domestic licensure & mfg (includes \$159,000 in additional funding for storage and stability)	221.2	
ASPR -- Contract awarded (5/1/06) to Solvay Purpose - Contract issued for the advanced develop. of cell-based pan flu vaccines for domestic licensure & mfg	299.0	
ASPR -- Contract awarded (5/1/06) to DynPort Purpose - Contract issued for the advanced develop. of cell-based pan flu vaccines for domestic licensure & mfg	41.0	
Cumulative Obligations, Accelerate Cell-Based Vaccine	953.2	0.0
<i>Unobligated Balances, Accelerate Cell-Based Vaccine</i>	<i>56.8</i>	<i>842.0</i>
RETROFIT OF FACILITIES FOR EMERGENCY PRODUCTION OF VACCINE	100.0	200.0
ASPR -- Contract awarded (6/14/07) to sanofi pasteur Purpose - Contract issued for the retrofitting of facilities for the emergency production of influenza vaccine	77.4	
ASPR -- Contract awarded (6/14/07) to MedImmune Purpose - Contract issued for the retrofitting of facilities for the emergency production of influenza vaccine	22.6	32.5
Cumulative Obligations, Retrofit of Facilities	100.0	32.5
<i>Unobligated Balances, Retrofit of Facilities</i>	<i>0.0</i>	<i>167.5</i>
ADVANCED DEVELOPMENT OF ANTIGEN-SPARING TECHNIQUES	140.0	110.0
ASPR -- Contract to GSK (Advanced Development of Antigen-Sparing) 1/4/07 Purpose - Contract issued for the advanced development of antigen sparing techniques	63.0	
ASPR -- Contract to IOMAI (Advanced Development of Antigen-Sparing) 1/4/07 Purpose - Contract issued for the advanced development of antigen sparing techniques	15.0	
ASPR -- Contract to Novartis (Advanced Development of Antigen-Sparing) 1/4/07 Purpose - Contract issued for the advanced development of antigen sparing techniques	55.0	
Cumulative Obligations, Advanced Development of Antigen-Sparing Techniques	133.0	0.0
<i>Unobligated Balances, Advanced Development of Antigen-Sparing Techniques</i>	<i>7.0</i>	<i>110.0</i>
FDA ACTIVITIES	20.0	0.0
FDA -- Contracts for IT Development and Maintenance, Technical and Contractual Support Services, Renovations for Quality Controlled Labs, Fraudulent Flu Awareness Campaign; Events Mgmt., and Publications.	7.6	
FDA -- Purchase of Lab Supplies, i.e. Biological Materials and Chemicals; Personal Protective Emergency Equipment/Materials for Field Investigators; Medical and Scientific Lab Equipment, i.e. Centrifuge, Gas Chromatograph System, Voltammetric Digital Analyzer System, Spectrometer; IT Equipment	7.3	
FDA -- Program Management Costs - salaries and benefits; rent; travel and transportation; training; meetings and workshops; and miscellaneous	3.9	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Cumulative Obligations, FDA	18.8	0.0
Unobligated Balances, FDA	1.2	0.0
PROGRAM MANAGEMENT		
Cumulative Obligations, Program Management	15.8	0.0
Unobligated Balances, Program Management	0.0	0.0
Cumulative Obligations, Vaccine	1,510.0	32.5
Unobligated Balances, Vaccine	271.0	1,419.5
Antivirals Funding	731.0	350.0
FEDERAL STOCKPILE & CONTAINMENT EFFORT	361.0	150.0
CDC -- Pandemic Flu Antivirals; Tamiflu (Roche) and Relenza (GSK) Purpose - Procure a supply of treatment courses of antivirals for the Strategic National Stockpile.	361.0	120.0
Cumulative Obligations, Federal Stockpile & Containment Efforts	361.0	120.0
Unobligated Balances, Federal Stockpile & Containment Efforts	0.0	30.0
SUBSIDIZE STATE PURCHASE OF ANTIVIRALS	170.0	0.0
ASPR -- State Pandemic Flu Antivirals Contracts; Tamiflu (Roche) and Relenza (GSK) Purpose - Allow States to purchase antivirals at subsidized Federal government price.	76.5	
Cumulative Obligations, Subsidize State Purchase of Antivirals	76.5	0.0
Unobligated Balances, Subsidize State Purchase of Antivirals	93.5	0.0
ADVANCED DEVELOPMENT OF PROMISING ANTIVIRAL DRUGS	200.0	200.0
ASPR -- Contract Awarded to BioCrist (Peramavir, Promising Antiviral) Purpose - Contract issued for the acquisition of promising antiviral	102.7	
Cumulative Obligations, Advanced Development of Promising Antiviral Drugs	102.7	0.0
Unobligated Balances, Advanced Development of Promising Antiviral Drugs	97.3	200.0
Cumulative Obligations, Antivirals	540.2	120.0
Unobligated Balances, Antivirals	190.8	230.0
Medical Supplies (PPE, ventilators, etc.) Funding	162.0	8.0
CDC -- N-95 respirators Purpose - Purchase of 62.5 million N-95 respirators for potential distribution to affected areas in case of an influenza pandemic.	50.0	
CDC -- Ventilators, syringes, IV antibiotics, and Storage & Security from various suppliers	107.3	
Cumulative Obligations, Medical Supplies	157.3	0.0
Unobligated Balances, Medical Supplies	4.7	8.0
State and Local Preparedness Funding	350.0	250.0
CDC -- Cooperative Agreements for special projects of national significance.		
ALASKA DEPT OF HEALTH & SOCIAL SERVICES	1.6	
OREGON DEPT OF HUMAN SERVICES	4.2	
WASHINGTON STATE DEPARTMENT OF HEALTH	6.6	
IDAHO DEPT. OF HEALTH AND WELFARE	2.3	
VERMONT DEPARTMENT OF HEALTH	1.6	
MAINE DEPT OF HUMAN SERVICES	2.2	
CONNECTICUT DEPT OF PUBLIC HEALTH	4.1	
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH	6.7	
RHODE ISLAND DEPARTMENT OF HEALTH	2.0	
NH DIVISION OF PUBLIC HEALTH SERVICES	2.2	
NY STATE DOH/HEALTH RESEARCH, INC.	11.0	
NEW JERSEY DEPT OF HEALTH/SENIOR SERVICE	8.8	
MHRA/NYC DOH	8.3	
VIRGIN ISLANDS DEPARTMENT OF HEALTH	0.3	
PUERTO RICO DEPARTMENT OF HEALTH	4.5	
DISTRICT OF COLUMBIA DEPT OF HEALTH	1.5	
PENNSYLVANIA DEPT OF HEALTH	12.1	
DELAWARE HEALTH & SO. SERVICES	1.8	
WV DEPT OF HEALTH & HUMAN RESOURCES	2.6	
VIRGINIA DEPARTMENT OF HEALTH	7.7	
MARYLAND DEPT OF HEALTH & MENTAL HYGIENE	6.0	
TENNESSEE DEPARTMENT OF HEALTH	6.3	
SO. CAROLINA DEPT OF HEALTH AND ENVIRONMENTAL CONTROL	4.8	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
ALABAMA DEPARTMENT OF PUBLIC HEALTH	5.1	
NC DEPT OF HEALTH AND HUMAN SERVICES	8.7	
MISSISSIPPI STATE DEPT OF HEALTH	3.6	
FLORIDA DEPT. OF HEALTH	16.8	
GEORGIA DIVISION OF PUBLIC HEALTH	9.0	
KENTUCKY CABINET FOR HEALTH SCIENCE	4.7	
ILLINOIS DEPT OF PUBLIC HEALTH	9.9	
MINNESOTA DEPARTMENT OF HEALTH	5.6	
OHIO DEPT OF HEALTH	11.3	
WISCONSIN DEPARTMENT OF HEALTH/FAMILY SERVICES	6.0	
CHICAGO DEPARTMENT OF HEALTH	3.6	
MICHIGAN DEPARTMENT OF COMMUNITY HEALTH	10.3	
INDIANA STATE DEPARTMENT OF HEALTH	6.6	
ARKANSAS DEPARTMENT OF HEALTH	3.5	
OKLAHOMA STATE DEPT OF HEALTH	4.2	
NEW MEXICO DEPARTMENT OF HEALTH	2.7	
TEXAS DEPT OF STATE HEALTH SERVICE	21.3	
LOUISIANA DEPT OF HEALTH & HOSPITALS	5.1	
IOWA DEPARTMENT OF PUBLIC HEALTH	3.7	
MISSOURI DEPT OF HEALTH & SENIOR SERVICE	6.2	
NE DEPT OF HHS REGULATION & LICENSURE	2.6	
KANSAS DEPT OF HEALTH & ENVIRONMENT	3.5	
COLORADO DEPT OF PUBLIC HEALTH & ENVIRONMENT	5.2	
MONTANA DEPT OF PUBLIC HEALTH & HUMAN SERVICES	1.8	
UTAH DEPARTMENT OF HEALTH	3.2	
SOUTH DAKOTA DEPARTMENT OF HEALTH	1.7	
WYOMING DEPARTMENT OF HEALTH	1.5	
ND DEPARTMENT OF HEALTH	1.6	
NEVADA DEPT. OF HEALTH & HUMAN SERVICES	3.1	
HAWAII DEPARTMENT OF HEALTH	2.1	
ARIZONA DEPT OF HEALTH SERVICES	6.2	
GUAM DEPT OF PUBLIC HEALTH/SOCIAL SERVICES	0.4	
LOS ANGELES CO DEPT OF HEALTH SERVICES	10.1	
CALIFORNIA DEPARTMENT OF HEALTH SERVICES	24.4	
COMMONWEALTH OF N. MARIANA ISLANDS	0.3	
REPUBLIC OF THE MARSHALL ISLANDS	0.3	
REPUBLIC OF PALAU	0.2	
FEDERATED STATES OF MICRONESIA	0.3	
AMERICAN SAMOA GOVERNMENT DOH	0.3	
NATIONAL GOVERNORS ASSOCIATION	0.9	
Cumulative Obligations, State and Local Preparedness	<u>326.2</u>	<u>0.0</u>
<i>Unobligated Balances, State and Local Preparedness</i>	<i>23.8</i>	<i>250.0</i>
International Activities Funding	<u>125.0</u>	<u>54.0</u>
INTERNATIONAL SURVEILLANCE	<u>89.0</u>	<u>35.0</u>
CDC -- Personnel stationed at international surveillance regions	4.4	2.6
CDC -- International Travel for the Outbreak Monitoring Team and to assess preparedness	0.7	0.1
CDC -- Personnel costs associated with International Surveillance	0.4	0.0
CDC -- Various contracts and IAAs under \$75,000 each		0.8
CDC -- Grant for Intl. Surv. In China: China National Influenza Center	0.4	
Purpose -- Development of influenza surveillance networks in China		
CDC -- Grant for Intl. Surv. In Bangkok: Thai Institute of Health	0.5	
Purpose - Development of influenza surveillance networks in Thailand		
CDC -- International Surveillance Grant: Kenya	0.2	
Purpose - Support influenza surveillance activities		
CDC -- Cote d'Ivoire Intl. Surveillance: Comforce Technical Services contract	0.1	
Purpose - International Technical Operational and Professional Support Services in Cote d'Ivoire		
CDC -- International Surveillance Grant: Cote d'Ivoire	0.3	
Purpose - Support influenza surveillance activities		
CDC -- Central Asia Intl. Surveillance: Technology Management Company	0.8	
Purpose - Technical and Logistical Support Services in Central Asia		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- Grant for Intl. Surv. In Central Asia: Kazakhstan Ministry of Health	0.3	
Purpose - Development of influenza surveillance networks in Central Asia		
CDC -- Grant for Intl. Surv. In Uganda: Makerere Univ. Institute of Public Health	0.2	
Purpose - Prevention and surveillance studies in Uganda		
CDC -- Rwanda Intl. Surveillance: Comforce Technical Services contract	0.2	
Purpose - International Technical Operational and Professional Support Services in Rwanda		
CDC -- Grant for Intl. Surv. In Rwanda: Columbia University Health Services	0.2	
Purpose - Prevention and surveillance studies in Uganda		
CDC -- Intl. Surv. IT Services: Northrop Grumman IT Services	0.2	
Purpose - IT support		
CDC -- International Surveillance Grant: Cambodia	0.6	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Cambodia	0.2	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Cambodia	0.2	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Vietnam	0.9	0.4
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Afghanistan	0.1	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Afghanistan	0.3	
Purpose - Support influenza surveillance activities		
CDC -- Korea Intl. Surv. Grant: National Influenza Center	0.2	
Purpose - Development of influenza surveillance networks in Korea		
CDC -- International Surveillance Interagency Agreement (IAA): NAMRU 2	1.5	
Purpose - Support influenza surveillance activities		
CDC -- Pacific Intl. Surv. Grant: Secretariat of the Pacific	0.3	
Purpose - Development of Pacific public health surveillance network		
CDC -- International Surveillance Grant: WHO/ Manila	0.9	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: WHO/ New Delhi	0.8	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: WHO/ Brazzaville	0.8	
Purpose - Support influenza surveillance activities		
CDC -- Intl. Surv. Grant: Pan American Health Organization	0.9	
Purpose - Coordination of comprehensive emerging infectious disease plans		
CDC -- International Surveillance Grant: WHO/ Egypt	2.1	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: WHO/ Denmark	0.8	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: WHO HQ	6.0	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Argentina	0.9	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Mexico	0.9	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Peru	0.8	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Armenia	0.4	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Georgia	0.4	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Romania	0.6	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Ukraine	0.6	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Morocco	0.6	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance IAA: NAMRU 3	1.5	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Nigeria	0.3	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Purpose - Support influenza surveillance activities		
CDC -- Nigeria Intl. Surv. Grant: University of Maryland		0.1
Purpose - Prevention and surveillance activities		
CDC -- Nigeria Intl. Surveillance: Comforce Technical Services contract		0.3
Purpose - International Technical Operational and Professional Support Services in Nigeria		
CDC -- International Surveillance: Comforce Technical Services contract		0.2
Purpose - Support influenza surveillance activities in Nigeria		
CDC -- International Surveillance: Comforce Technical Services contract		0.2
Purpose - Support influenza surveillance activities in Tanzania		
CDC -- Tanzania Intl. Surveillance: Comforce Technical Services contract		0.1
Purpose - International Technical Operational and Professional Support Services in Tanzania		
CDC -- International Surveillance Grant: Tanzania		0.1
Purpose - Support influenza surveillance activities		
CDC -- Ethiopia Intl. Surv. Grant: Ethiopian Health and Nutrition Inst.		0.1
Purpose - Surveillance and lab activities		
CDC -- Ethiopia Intl. Surv. Grant: JHPIEGO		0.3
Purpose - Surveillance and lab activities		
CDC -- Laos Intl. Surv. Grant: CARE		0.4
Purpose - Surveillance and lab activities		
CDC -- International Surveillance Grant: Laos		0.1
Purpose - Support influenza surveillance activities		
CDC -- Mongolia Intl. Surv. Grant: Ministry of Health Mongolia		0.6
Purpose - Development of influenza surveillance networks in Mongolia		
CDC -- Indonesia Intl. Surv. Grant: Ministry of Health, Indonesia		1.3
Purpose - Development of influenza surveillance networks in Indonesia		
CDC -- Philippines Intl. Surv. Grant: Department of Health, National Influenza Center		0.6
Purpose - Development of influenza surveillance networks in the Philippines		
CDC -- Malaysia Intl. Surv. Grant: Ministry of Health, Malaysia		0.7
Purpose - Development of influenza surveillance networks in Malaysia		
CDC -- India Intl. Surv. Grant: Indian Council of Medical Research		1.6
Purpose - Development of influenza surveillance networks in India		
CDC -- Pakistan Intl. Surv. Grant: National Institutes of Public Health		0.5
Purpose - Development of influenza surveillance networks in Pakistan		
CDC -- International Surveillance Grant: Bangladesh		0.4
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Brazil		0.8
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance Grant: Turkey		0.1
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance IAA: COGH Business Services Unit		0.2
Purpose - International Staffing		
CDC -- International Staffing Intl. Surveillance: Comforce Technical Services contract		0.2
Purpose - International Technical Operational and Professional Support Services		
CDC -- International Staffing Intl. Surveillance: Professional and Scientific Associations Inc.		1.5
Purpose - International Travel and Logistical Support Services		
CDC -- International Surveillance grant: WPRO		0.8
Purpose - Support influenza surveillance activities through international staffing		
CDC -- International Surveillance grant: PAHO		0.4
Purpose - Support influenza surveillance activities through international staffing		
CDC -- International Surveillance grant: TEPHENET		0.2
Purpose - Conference support		
CDC -- International Staffing Intl. Surv. Grant: WHO		0.3
Purpose - Special Cooperative Health Investigations & Assignments		
CDC -- International Staffing Intl. Surv. Grant: University of Maryland		0.2
Purpose - Prevention and Surveillance Activities		
CDC -- International Surveillance: Thompson, Cobb, Bazilio & Associates contract		0.1
Purpose - Accounting and budgetary assistance concerning international surveillance activities		
CDC -- Bangkok International Surveillance:		1.8
Purpose - Cable for consulting services in Bangkok		
CDC -- Bangkok International Surveillance:		0.2
Purpose - Cable for consulting services in Bangkok		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- China Intl. Surv. Grant: China Centers for Disease Control and Prevention	1.5	
Purpose - Prevention and Surveillance Activities		
CDC -- International Surveillance IAA: COGH Business Services Unit	0.3	
Purpose - Support influenza surveillance activities		
CDC -- International Surveillance IAA: Booz Allen	0.1	
Purpose - International Surveillance technical assistance		
CDC -- International Surveillance: McKing Consulting Corp. contract	0.1	
Purpose - Outreach and Technical Assistance to International Communications Partners		
CDC -- Guatemala Intl. Surv. Grant: Universidad del valle de Guatemala	0.03	
Purpose - Research in Human Infectious Diseases in Guatemala		
CDC -- Various contracts and IAAs under \$75,000 each	1.8	
Purpose - Technical assistance, supplies, and equipment to support International Surveillance activities		
ASPR -- Supplement Grant to Bangladesh	1.1	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Supplement Grant to Central Asia Platform	1.5	
Purpose - To support preparedness, containment and risk communication activities		
ASPR -- Supplement Grant to China	0.4	
Purpose - To support preparedness, containment and risk communication activities		
ASPR -- Supplement Grant to India	0.4	
Purpose - To support preparedness, communication and response activities		
ASPR -- Supplement Grant to Indonesia	1.9	
Purpose - To support detection, containment and communication activities		
ASPR -- Supplement Grant to Malaysia	0.4	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to Mongolia	0.4	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to Pakistan	0.4	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to Philippines	0.4	
Purpose - To support risk communication, preparedness and containment activities		
ASPR -- Grant to Ukraine	0.4	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to WPRO (Laos, Vietnam)	0.3	
Purpose - To support effective risk communication activities		
ASPR -- Supplement Grant to WPRO (Cambodia)	0.8	
Purpose - To support effective risk communication/containment activities		
ASPR -- Supplement Grant to Bangkok Regional Site	1.0	
Purpose - To support response and containment activities		
ASPR -- Supplement Grant to WHO-AFRO Brazza-ville	0.5	
Purpose - To support response and containment activities		
ASPR -- Supplement Grant to WHO-AFRO Brazza-ville	0.4	
Purpose - To provide expert staffing support		
ASPR -- Supplement Grant to WHO Egypt EMRO	0.5	
Purpose - To provide expert support		
ASPR -- Grant to Kenya Regional Site	0.1	
Purpose - To support preparedness and communication activities		
ASPR -- Grant to Kenya Regional Site	1.0	
Purpose - To support response and containment activities		
ASPR -- IAA with CDC to Establish International Stockpile	0.3	
Purpose - To support response and containment activities		
ASPR -- Supplement to Grant to WHO for Pan Flu Rapid Response and Early Containment Project	1.0	
Purpose - To support response and containment activities		
ASPR -- IAA with FDA for regulatory preparedness workshops	0.5	
Purpose - To support effective risk communication activities		
ASPR -- Grant to WHO Headquarters (In-Country Vaccine Development, Various Countries)	10.0	
Purpose - To support response and containment activities		
ASPR -- Grant to the Institute Pasteur Network (S.E. Asia and Africa)	1.6	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Grant to the Gorgas Memorial Institute (Panama)	0.8	
Purpose - To support preparedness and risk communication activities		
ASPR -- Grant to the Gorgas Memorial Institute (Panama)	2.5	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Purpose-To support response and containment activities		
ASPR -- Supplement Grant for Outbreak Investigation Support	0.8	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Smithsonian Tropical Research Institute Bird Monitoring	0.2	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- South Africa Field Epidemiology and Lab Training Program (FELTP)	0.4	
Purpose - To support response and containment activities		
ASPR -- Supplement Grant for Critical Outcome Evaluation	0.1	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant for Distance Learning: Surveillance & Response	0.1	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to the West Africa FELTP	0.2	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Supplement Grant to Nigeria FELTP	0.2	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Supplement Grant to WHO Specimen transport fund.	0.5	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Contract Modification for the Monitoring and Evaluation of Influenza Programs (RAND)	0.5	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to Mexico to assist in set-up of operations center	0.1	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Contract modification to fund an IOM meeting on influenza containment	0.1	
Purpose - To support preparedness and risk communication activities		
ASPR -- Contract to Team PSA for WHO/ASEAN/US Stockpile and Tri-lateral SPP coordination meeting	0.1	
Purpose - To support preparedness and risk communication activities		
ASPR -- IAA with NIH/NIGMS to Support Modeling of disease spread in SE Asia (MIDAS)	0.2	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Supplement grant to support an infectious disease workshop at the University of Cape Town	0.1	
Purpose - To support preparedness and risk communication activities		
ASPR -- Supplement Grant to the Smithsonian Tropical Research Institute (Panama)	0.1	
Purpose - To support preparedness, surveillance and containment activities		
ASPR -- Supplement Grant to support the Multinational Influenza Seasonal Mortality Study Group	0.1	
Purpose - To support preparedness and risk communication activities		
OGHA -- Supplement Grant to Angola	0.8	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Afghanistan	0.8	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Brazil	0.1	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Turkey	0.3	
Purpose - To support surveillance and detection activities		
OGHA -- Grant to REDI Center	2.1	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Iraq	0.4	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Kenya	0.2	
Purpose - To support surveillance and detection activities		
OGHA -- IAA for ISTC & STCU	0.8	
Purpose - To support preparedness and risk communication activities		
OGHA -- Supplement Grant to Libya	1.0	
Purpose - To support surveillance and detection activities		
OGHA -- Supplement Grant to Mexico	0.1	
Purpose - To support surveillance and detection activities		
OGHA -- Influenza Strategic Management Unit	0.6	
Purpose - To support the management and administration of AI activities		
Cumulative Obligations, International Surveillance	89.2	3.8
<i>Unobligated Balances, International Surveillance</i>	<i>(0.2)</i>	<i>31.2</i>
RAPID RESPONSE	15.0	15.0
CDC -- Travel & Personnel costs associated with Rapid Response	0.1	0.1
CDC -- International Rapid Response Funding: Various contracts and IAAs under \$75,000 each	0.1	0.1
Purpose - Technical assistance, supplies, and equipment to support Rapid Outbreak Response activities		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- Rapid Response contract: China	0.2	
Purpose - Provide pan flu infrastructure support via cable		
CDC -- Rapid Response Grant: China Centers for Disease Control and Prevention	1.7	
Purpose - Prevention and surveillance activities and studies in China		
CDC -- Rapid Response IAA: USAID/Bangkok	0.7	
Purpose - Provide supplies and materials in Bangkok		
CDC -- Rapid Response contract: Bangkok	1.8	
Purpose - Provide pan flu infrastructure support via cable		
CDC -- Rapid Response Grant: Bangkok	0.1	
Purpose - Pan flu preparedness in Bangkok		
CDC -- Rapid Response Grant: Bangkok	0.7	
Purpose - Pan flu preparedness in Bangkok		
CDC -- Rapid Response Grant: WHO	0.6	
Purpose - Special cooperative health investigations & assessments in Thailand		
CDC -- Rapid Response Grant: Department of Medical Sciences	0.5	
Purpose - Special cooperative health investigations & assessments in Thailand		
CDC -- Rapid Response contract: Kenya	1.8	0.1
Purpose - Provide pan flu infrastructure support via cable		
CDC -- Rapid Response IAA: CID	0.2	
Purpose - Supplies and materials in Kenya		
CDC -- Rapid Response Grant: Kenya	1.9	
Purpose - Pan Flu preparedness in Kenya		
CDC -- Rapid Response Grant: Guatemala	1.9	
Purpose - Pan Flu preparedness in Guatemala		
CDC -- Rapid Response Grant: Guatemala	0.8	
Purpose - Pan Flu preparedness in Guatemala		
CDC -- Rapid Response IAA: Egypt Embassy	1.2	
Purpose - Infrastructure support in Egypt		
CDC -- Rapid Response Grant: National Institute for Communicable Diseases	0.9	0.02
Purpose - Enhancement of surveillance in South Africa		
CDC -- Rapid Response IAA: ICASS	0.1	
Purpose - Infrastructure support in Vietnam		
Cumulative Obligations, Rapid Response	15.0	0.3
<i>Unobligated Balances, Rapid Response</i>	<i>0.0</i>	<i>14.7</i>
HUMAN ANIMAL INTERFACE	3.0	4.0
CDC -- Travel & Personnel costs associated with Human Animal Interface	0.2	
CDC -- Various contracts and IAAs under \$75,000 each	0.01	
Purpose - Avian Influenza research		
CDC -- Human Animal Interface Grant: Mahidol University	0.9	
Purpose - Avian Influenza Surveillance in Thailand		
CDC -- Human Animal Interface Grant: University of Georgia	0.2	
Purpose - Avian Influenza Surveillance in the environment		
CDC -- Human Animal Interface Grant: University of Minnesota	0.9	
Purpose - Avian Influenza Cooperative Research Centers		
CDC -- Human Animal Interface Grant: Colorado State University	0.9	
Purpose - Zoonotic Avian Influenza		
Cumulative Obligations, Human Animal Interface	3.0	0.0
<i>Unobligated Balances, Human Animal Interface</i>	<i>0.0</i>	<i>4.0</i>
NIH ACTIVITIES	18.0	0.0
NIH -- Contract to Oxford University	8.0	
Purpose - Expand Clinical Infrastructure and Research in SE Asia for Therapeutics, Diagnostics and Vaccines		
NIH -- Contract to Armed Forces Research Institute of Medical Sciences (AFRIMS)	3.0	
Purpose - Conduct studies in Vietnam and China to determine the presence of antibodies against H5N1 in potentially exposed individuals		
NIH -- Grant to National Center for AIDS Prevention and Control (People's Republic of China)	4.0	
Purpose - Conduct studies in China to investigate H5N1 antibody prevalence and characterize virus from animals and humans in SE Asia		
NIH -- Contracts to Family Health International and PPD Development	2.0	
Purpose - Clinical studies support		
NIH -- Contract to St. Judes Children's Hospital	1.0	
Purpose - Expand human-animal interface surveillance studies in SE Asia		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Cumulative Obligations, NIH Activities	18.0	0.0
<i>Unobligated Balances, NIH Activities</i>	<i>0.0</i>	<i>0.0</i>
Cumulative Obligations, International Activities	125.0	4.1
<i>Unobligated Balances, International Activities</i>	<i>0.0</i>	<i>49.9</i>
Other Domestic Activities Funding	138.0	138.0
VACCINE REGISTRY	6.0	10.0
CDC -- Vaccine Registry: Northrop Grumman Information contract	2.2	
Purpose - Pandemic Influenza functionality addition to the Vaccine Ordering and Distribution System (VODS) to support CDC pandemic planning and operations.		
CDC -- Vaccine Registry: IAA	3.4	
Purpose - Enhance CRA functionality		
Cumulative Obligations, Vaccine Registry	5.5	0.0
<i>Unobligated Balances, Vaccine Registry</i>	<i>0.5</i>	<i>10.0</i>
QUARANTINE	20.0	15.0
CDC -- Travel & Personnel Costs associated with Quarantine	1.2	0.2
CDC -- Various contracts and IAAs under \$75,000 each	0.9	0.02
Purpose - Technical assistance, consulting, supplies, and equipment supporting quarantine activities		
CDC -- Quarantine: Regents of the University of Michigan contract	0.8	
Purpose - Quarantine flu research		
CDC -- Quarantine: Professional & Scientific Associates Inc. contract	0.1	
Purpose - Planning and management of pan flu conference		
CDC -- Quarantine: Northrop Grumman Information Technology Inc. contract	2.0	
Purpose - Technical support of DHQP pan flu preparedness activities		
CDC -- Quarantine: Lockheed Martin Services Inc. contract	0.5	
Purpose - Professional and technical support for NCID quarantine activities		
CDC -- Quarantine: McKing Consulting Corporation contract	0.3	0.1
Purpose - Management Consultation and Technical Assistance, Quarantine: Operational and Legal Assessment		
CDC -- Quarantine: Policy Navigation Group contract	0.3	
Purpose - Pan flu quarantine legislative support		
CDC -- Quarantine: Research Triangle Institute contract	0.8	
Purpose - Provide services for program policy assessments and evaluation design for Quarantine Training and Education Needs		
CDC -- Quarantine: McKing Consulting Corp. contract	0.1	
Purpose - Management consultation and technical assistance for quarantine		
CDC -- Quarantine: Knowledge Factor Inc. contract	0.2	
Purpose - Pan Flu learning assessment, creation of core curriculum, and evaluation		
CDC -- Quarantine: ENV Services Inc. contract	0.1	
Purpose - Biosafety cabinets		
CDC -- Quarantine: National Associates Inc. contract	0.1	
Purpose - Media Relations Specialist responsible for providing support, expertise, advice and technical assistance related to CDC's pandemic influenza preparedness and response programs.		
CDC -- Quarantine: HHS/HRSA & PSC IAA	0.4	
Purpose - Support quarantine infrastructure at ports of entry for pandemic flu preparedness		
CDC -- Quarantine: Dept. of Energy IAA	0.4	
Purpose - To support table top exercises on pandemic flu (quarantine system)		
CDC -- Quarantine: OPM IAA	0.2	
Purpose - To support pandemic flu simulation project		
CDC -- Quarantine: COMMERCE/NIST IAA	0.1	
Purpose - Micro Computer support services		
CDC -- Quarantine: SAMHSA IAA	0.1	
Purpose - Purchase Adverse Drug Event data from SAMHSA		
CDC -- Quarantine: NCPHI IAA	0.8	
Purpose - Development of Patient Flu Vaccination Compliance Module & State Health Dept Data Sharing & complete/deploy healthcare personnel safety vaccine module		
CDC -- Quarantine: Dept. of Energy IAA	0.1	
Purpose - Public Healthcare Preparedness for DHQP		
CDC -- Quarantine: ORISE IAA	0.3	
Purpose - Tabletop exercises for healthcare preparedness		
CDC -- Quarantine: OPM IAA	0.6	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Purpose - Expansion of infection control capacity (nat'l response & training)		
CDC -- Quarantine Grant: World Health Organization	0.1	
Purpose - Special cooperative health investigations & assessments		
CDC -- Quarantine Grant: Emory University	0.1	
Purpose - Cooperative agreement for pan flu assistance		
CDC -- Quarantine Grant: Regents of University of Michigan	1.1	
Purpose - Reducing transmission of influenza by face masks		
CDC -- DGMQ-OD Quarantine Grant: Trustees of Columbia University	1.1	
Purpose - Stopping upper respiratory infections and flu in the family-the stuffy trial		
CDC -- Quarantine Grant: University of Otago	0.4	
Purpose - Pandemic influenza control at the borders of island countries and in household		
CDC -- Quarantine Grant: University of Massachusetts-Lowell	0.3	
Purpose - Evaluation of masks as a source control NPI (non-pharmaceutical intervention)		
CDC -- Quarantine Grant: Regents of the University of California	0.5	
Purpose - Effectiveness of selected non-pharmaceutical interventions in reducing influenza like illness among students		
CDC -- Quarantine Grant: University of Pittsburgh	0.8	
Purpose - Pittsburgh influenza prevention project		
CDC -- Quarantine Grant: Research Triangle Institute	0.8	
Purpose - Non-pharmaceutical interventions for pandemic influenza		
CDC -- Quarantine Grant: University of Hong Kong	0.3	
Purpose - Cooperative agreement for pandemic influenza assistance		
CDC -- Quarantine Grant: #007277 DGMQ-QBHSB	0.2	
Purpose - To support and train quarantine system personnel for pandemic readiness		
CDC -- Quarantine Grant: International Rescue Committee	0.3	
Purpose - Improving detection, surveillance, and response for influenza in immigrants & refugees		
CDC -- Quarantine Grant: Regents of University of Minnesota	0.5	
Purpose - Early detection, surveillance, and response for highly pathogenic influenza A viruses		
CDC -- Quarantine Grant: SMRU-faculty of Tropical Medicine	0.3	
Purpose - Avian flu surveillance network in displaced populations on the Thai Burma border		
CDC -- Quarantine Grant: The Association of State and Territorial Health Officials (ASTHO)	0.2	
Purpose - Nursing and Epidemiologist Cooperative Agreement to Enhance BioSurveillance Capabilities		
CDC -- Quarantine Grant: International Society of Tropical Medicine	0.3	
Purpose - Global surveillance network to detect influenza among travelers and other outbreaks of public health significance		
CDC -- DHQP Quarantine Grant: Cooperative Agreement with Wake Forest	0.4	
Purpose - Aerobiology study of mask & respirator efficacy to prevent respiratory viral infection in a human model		
CDC -- Quarantine Grant: The Medstat Group contract	0.0	
Purpose - Patient claims database		
CDC -- Quarantine Grant: Johns Hopkins University	0.0	
Purpose - Analysis of legal implications of quarantine during pandemic influenza (state, local, and federal authorities)		
Cumulative Obligations, Quarantine	17.9	0.4
Unobligated Balances, Quarantine	2.1	14.6
LAB CAPACITY	50.0	30.0
CDC -- Travel & Personnel Costs associated with Lab Capacity	9.8	1.4
CDC -- Various contracts and IAAs under \$75,000 each	4.4	0.1
Purpose - Technical assistance, consulting, supplies, and equipment supporting lab capacity activities		
CDC -- Lab Capacity: Professional & Scientific Associates Inc. contract	0.1	
Purpose - International travel and logistical support services		
CDC -- Lab Capacity: Los Alamos National Lab IAA	0.3	
Purpose - Influenza viral sequence database		
CDC -- Lab Capacity Grant: Marshall Clinic Research Foundation	0.5	
Purpose - Rapid Analysis of Influenza Vaccine Effectiveness		
CDC -- Lab Capacity Grant: Mount Sinai	0.3	
Purpose - Development of Guinea Pig as a mammalian for Influenza Virus Transmission		
CDC -- Lab Capacity Grant: University of Maryland	0.2	
Purpose - Mechanisms of Influenza a Virus Transmission in Ferrets		
CDC -- Lab Capacity Grant: Oregon State University	0.2	
Purpose - Replication of Highly Pathogenic Avian Influenza Viruses in Swine		
CDC -- Lab Capacity Grant: Iowa State University	0.4	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Purpose - Pathogenesis of Infections in Swine with Pathogenic Avian Influenza Virus CDC -- Lab Capacity Grant: #OCCU007277		2.1
Purpose - To support and train quarantine system personnel for pandemic readiness CDC -- Lab Capacity Grant: Association of Public Health Laboratory		0.8
Purpose - National laboratory training and management information systems CDC -- Lab Capacity Grant: University of Georgia		0.7
Purpose - Avian Influenza Viruses in the Environment: What is probability of Human Contact CDC -- Lab Capacity Grant: National Institute of Public Health & Environment, Netherlands		0.3
Purpose - Avian influenza CRC studies at the Human-animal interface CDC -- Lab Capacity: OPM IAA		0.3
Purpose - Support services through Booz-Allen-Hamilton CDC -- Lab Capacity: Biomerieux Inc. contract		5.0
Purpose - Easy mag extraction system CDC -- Lab Capacity: McKing Consulting Corp. contract		1.4
Purpose - Management consultation and technical assistance CDC -- Lab Capacity: Consolidated Safety Services Inc. contract		0.1
Purpose - Bio safety training for federal employees CDC -- Lab Capacity: The Scripps Research Inst. Contract		0.4
Purpose - Influenza binding assays CDC -- Lab Capacity: Atlanta Veterans Affairs Medical Center IAA		2.0
Purpose - Improved diagnostics for viral causes of infectious diseases CDC -- Lab Capacity: Indian Health Service IAA		0.1
Purpose - Preventing infectious diseases among residents of Arctic & Sub-Arctic CDC -- Lab Capacity: Computer Sciences Corporation contract		0.2
Purpose - Worksite health promotion CDC -- Lab Capacity: Roche Diagnostics Corp. contract		0.2
Purpose - Genome sequencer 20 instrument CDC -- Lab Capacity: Government Scientific Source Inc. contract		0.2
Purpose - Sakura Tissue Tek Auto TEC Embedding CDC -- Lab Capacity: Krug Inc. contract		0.1
Purpose - Office furniture and equipment CDC -- Lab Capacity: Lyme Computer Systems Inc. contract		0.1
Purpose - Mat lab for hi-throughput lab CDC -- Lab Capacity: Beckman Coulter Inc.		0.1
Purpose - Vi cell system CDC -- Lab Capacity: Westwood Computer Corp. contract		0.2
Purpose - Computer equipment CDC -- Lab Capacity: Applera Corp. contract		0.1
Purpose - Array upgrade kit CDC -- Lab Capacity: Amersham Biosciences contract		0.2
Purpose - AKTAEXPLORER 100 CDC -- Lab Capacity: Xenogen contract		0.3
Purpose - IVIS SYSTEM 120V CDC -- Lab Capacity: AFFYMETRIX Inc. contract		0.2
Purpose - Work station CDC -- Lab Capacity: Immix Technology Inc.		0.1
Purpose - 300 GB, 10k RPM, UNIVERSAL FC DISK, appliance, and software CDC -- Lab Capacity: Carl Zeiss Microimaging Inc. contract		0.1
Purpose - Microimaging equipment CDC -- Lab Capacity: Applera Corp. contract		0.3
Purpose - 96 CAP DNA ANALYZER CDC -- Lab Capacity: Global Technology Solutions contract		0.2
Purpose - Sunrack CDC -- Lab Capacity: Goldbelt Raven Inc. contract		0.1
Purpose - iCYCLER THERMAL CYCLER-96-WELL and Versadoc 5000 system CDC -- Lab Capacity: Government Scientific Source Inc. contract		0.1
Purpose - Gene Pix scanner and desktop CDC -- Lab Capacity: Roche Diagnostics Corp. contract		0.2
Purpose - MagNaPure LC with Light Cycler CDC -- Lab Capacity: Applera Corp. contract		0.1
Purpose - ABI 7500		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- Lab Capacity: Biaera Technologies Inc. Purpose - AERomp AUTOMATION INTERFACE MODULE	0.1	
CDC -- Lab Capacity: Biacore Inc. contract Purpose - BIOCORE T-100 UNIT	0.3	
CDC -- Lab Capacity: Progroup Instrument Inc. contract Purpose - Well Pro WP 3000	0.1	
CDC -- Lab Capacity: Beta South Technology Inc. Purpose - cycler system II and smart system	0.1	
CDC -- Lab Capacity: Goldbelt Raven LLC contract Purpose - MJ Tetrad Thermal Cyclers and Alpha Engine	0.1	
CDC -- Lab Capacity: Applied Biosystems contract Purpose - QST, 7500 Fast Real-Time, Tower, SV	0.1	
CDC -- Lab Capacity: Goldbelt Raven LLC contract Purpose - Qiagen BioRobot, equipment, and installation	0.2	
CDC -- Lab Capacity: Goldbelt Raven LLC contract Purpose - MX 3005P QPCR system and service	0.1	
CDC -- Lab Capacity: Biaera Technologies contract Purpose - PLA001a and other lab equipment	0.1	
CDC -- Lab Capacity: MPRI, Inc. contract Purpose - Draft pandemic operational plan and provide operational support	0.2	0.3
CDC -- Lab Capacity: Northrop Grumman Information Technology contract Purpose - Technical support of pan flu preparedness activities	0.4	
CDC -- Lab Capacity Grant: CARE Purpose - Technical support of pan flu preparedness activities	0.4	
CDC -- Lab Capacity: OPM IAA Purpose - Support services through Booz-Allen-Hamilton	0.3	
CDC -- Lab Capacity: IAA Purpose - Capacity building	0.2	
CDC -- Lab Capacity IAA: USAID Purpose - To systematically document and disseminate information about the National health care services infrastructure	0.1	
CDC -- Lab Capacity Grant: Nat Inst Pub Hlth & Environment, Netherlands Purpose - Avian influenza CRC studies at the Human-animal interface	0.1	
CDC -- Lab Capacity Grant: Direct Gen/Disease Control Jakarta Purpose - Surveillance & Response to Avian and Pandemic Influenza	0.1	
CDC -- Lab Capacity Grant: International Rescue Committee Purpose - Complex humanitarian emergency and war related injury	0.1	
CDC -- Lab Capacity Grant: Vietnam Veterans of America Foundation Purpose - Complex humanitarian emergency and war related injury	0.2	
CDC -- Lab Capacity: Batelle Memorial Institute contract Purpose - Support for the project entitled "Reaerosolization of Viruses from NIOSH-certified Filtering Facepiece Respirators"	0.1	
CDC -- Lab Capacity: EG&G Technical Services contract Purpose - Scientific, Professional and Engineering Support Services for the National Personal Protective Technology Laboratory	0.7	
CDC -- Lab Capacity: National Academy of Sciences contract Purpose - Provide Research Associates for the National Personnel Protective Laboratory (NPPTL)	0.1	
CDC -- Lab Capacity: McKing Consulting Corp. contract Purpose - Provide Office of Genomics and Disease Prevention (OGDP) with Management Consultation and Technical Assistance	0.4	
CDC -- Lab Capacity: America's Health Insurance Plans contract Purpose - Provide Office of Genomics and Disease Prevention (OGDP) with vaccine safety services	1.2	
CDC -- Lab Capacity: America's Health Insurance Plans IAA Purpose - Development of a influenza bio-bank in a managed care setting	1.0	
CDC -- Lab Capacity: Booz Allen Hamilton Inc. contract Purpose - Provide evaluation of pandemic influenza operational plan	0.3	
CDC -- Lab Capacity: MPRI, Inc. contract Purpose - Draft pandemic operational plan and provide operational support	1.4	
CDC -- Lab Capacity: DOD's Chemical and Biological Defense Information Analysis Center (CBIAC) Purpose - The purpose of this award is to engage CBIAC resources in research by providing scientific and technical services to DLS	0.5	
CDC -- Lab Capacity: Applera Corp. contract Purpose - Spectrometer package, Discovery system, and accessories	0.7	
CDC -- Lab Capacity: Thermo Electron Corp. contract	0.5	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Purpose - LTQ ORBITRAP/ESI Bundle		
CDC -- Lab Capacity: Waters Corp. contract	0.6	
Purpose - MS System, software, and equipment		
CDC -- Lab Capacity: Thermo Electron Corp. contract	0.6	
Purpose - LTQ ORBITRAP/ESI Bundle and software		
CDC -- Lab Capacity: Eksigent Technologies LLC contract	0.3	
Purpose - System, Nano LC-2D HPLC and warranty		
CDC -- Lab Capacity: STARLIMS Corp. contract	0.2	1.2
Purpose - StarLIMS Enterprise Development Kit and Implementation services		
CDC -- Lab Capacity IAA: GSA Rand	0.5	
Purpose - Provide tools to identify and address challenges at the national and regional levels related to planning surveillance and response to public health emergencies.		
CDC -- Lab Capacity IAA: ORISE	0.2	
Purpose - Design, coordinate, conduct and report on a series of meetings for regional public health- healthcare personnel to focus on issues of surge capacity relative to pandemic influenza response.		
CDC -- Lab Capacity: BL Seamon Corp. contract	0.1	
Purpose - Coordinate and manage 2007 Summit Meeting-Emergency Legal Preparedness & Public Health		
CDC -- Lab Capacity IAA: USAID	1.0	
Purpose - Enhance international efforts for wild bird surveillance for avian influenza		
CDC -- Lab Capacity Grant: American Society of Law Methods & Ethics	0.1	
Purpose - Building system capacity to apply law as a public health tool		
CDC -- Lab Capacity: University of Virginia contract	0.0	
Purpose - Pediatric serum survey		
CDC -- Lab Capacity: Lockheed Martin contract		0.2
Purpose - COTPER DEOC staffing		
CDC -- Lab Capacity: Northrop Grumman contract		0.5
Purpose - Develop and support the StarLIMS Laboratory Information Management Systems services		
CDC -- Lab Capacity: Lockheed Martin contract		0.2
Purpose - Consultation Service, Facilitation Services, Project Management and Technical Support to the National Center for Infectious Diseases (NCID)		
CDC -- Lab Capacity: Lockheed Martin contract		0.1
Purpose - DSNS staffing		
Cumulative Obligations, Lab Capacity	45.8	4.0
Unobligated Balances, Lab Capacity	4.2	26.0
BIOSENSE	35.0	0.0
CDC -- Travel & Personnel Costs associated with Biosense	0.9	
CDC -- Various contracts and IAAs under \$75,000 each	0.5	
Purpose - BioSense related management and technical assistance		
CDC -- BioSense: Northrop Grumman Information Technology contract	2.8	
Purpose - Technical support of pan flu preparedness activities		
CDC -- BioSense: STARLIMS Corp. contract	0.4	
Purpose - StarLIMS Enterprise Development Kit and Implementation services		
CDC -- BioSense: Lockheed Martin Services Inc. contract	0.5	
Purpose - Technical support of pan flu preparedness activities		
CDC -- BioSense Grant: Minnesota	0.2	
Purpose - Population based domestic surveillance		
CDC -- BioSense Grant: Association of Schools of Public Health, Inc.	0.1	
Purpose - For the improvement of interaction between PHAS and PHPS		
CDC -- BioSense Grant: The Association of State and Territorial Health Officials (ASTHO)	0.2	
Purpose - Nursing and Epidemiologist Cooperative Agreement to Enhance BioSurveillance Capabilities		
CDC -- BioSense Grant: Association of American Medical Colleges	0.1	
Purpose - Program improvements for schools of public health		
CDC -- BioSense: IAA	0.4	
Purpose - DEPR Healthcare IT Standard Integration		
CDC -- BioSense: McKing Consulting Corp. contract	0.3	
Purpose - DEPR Management Consultation for Biosense Infrastructure Support		
CDC -- BioSense IAA: Gartner	1.6	
Purpose - Independent Verification Validation of the BioSense Program		
CDC -- BioSense: Unisys Corp. contract	1.1	
Purpose - Equipment and supplies for DEPR Biosense Infrastructure Support		
CDC -- BioSense Grant: International Society of Disease Surveillance (ISDS)	0.6	
Purpose - Enhance the Capacities of Disease Surveillance		

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- BioSense Grant: Association of Public Health Laboratories Purpose - National Laboratory Training Network and Management Information Systems	1.8	
CDC -- BioSense Grant: The Association of State and Territorial Health Officials (ASTHO) Purpose - Nursing and Epidemiologist Cooperative Agreement to Enhance BioSurveillance Capabilities	0.5	
CDC -- BioSense IAA: Constella Purpose - Recruitment and Implementation of Data Sources for BioSense Application	4.9	
CDC -- BioSense IAA: SAIC Purpose - Access BioSurveillance Relevant Information from Pharmaceutical Data Sources	0.6	
CDC -- BioSense IAA: National Retail Data Monitoring (NRDM) Purpose - Access BioSurveillance Relevant Information from Over the Counter Retail Data Sources	0.5	
CDC -- BioSense IAA: GSA - Northrup and CSC Purpose - Develop and Support Decision System Specific to Influenza for use in the BioSense Application-Federal Information Systems Support (FISSP)	0.4	
CDC -- BioSense IAA: GSA Purpose - Develop and Support Decision System Specific to Influenza for use in the BioSense Application-Enterprise Information and Technical Infrastructure Technical Services (EITITS)	1.6	
CDC -- BioSense: Northrop Grumman Information Technology contract Purpose - Technical support of pan flu preparedness activities	0.1	
CDC -- BioSense: Atlanta Veteran's Affairs Medical Center Purpose - Epidemiologic Data Manager	0.2	
CDC -- BioSense: America's Health Insurance Plans Purpose - AREF - Improved diagnostics for viral causes of infectious diseases	2.1	
CDC -- BioSense Grant: Tennessee Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Colorado Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Oregon Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Connecticut Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: California Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Maryland Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: New York Purpose - Population based domestic surveillance	0.2	
CDC -- BioSense Grant: Georgia Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Minnesota Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense Grant: Cincinnati Children's Hospital Purpose - Population based surveillance for influenza among children	0.3	
CDC -- BioSense Grant: University of Rochester Purpose - Population based surveillance for influenza among children	0.3	
CDC -- BioSense Grant: Vanderbilt University Purpose - Population based surveillance for influenza among children	0.3	
CDC -- BioSense Grant: New Mexico Purpose - Population based domestic surveillance	0.1	
CDC -- BioSense IAA: GSA Purpose - To Fund the Epidemiology Career Training Program (ECTP)	0.4	
CDC -- BioSense: Unisys Corp. contract Purpose - Technical assistance for DISS Biosense Infrastructure Support	0.5	
CDC -- BioSense IAA: GSA Purpose - Build and Support the Secure Data Network	0.6	
CDC -- BioSense: Dataline Inc. contract Purpose - Data hardware and software for DISS Biosense Infrastructure	1.5	
CDC -- BioSense Grant: NAPHSIS Foundation Inc. Purpose - Vital Statistics Re-engineering Program	0.7	
Cumulative Obligations, Biosense	27.7	0.0
Unobligated Balances, Biosense	7.3	0.0
RAPID TESTS FUNDING	27.0	40.0
CDC -- Travel & Personnel Costs associated with Rapid Tests	0.9	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- Various contracts and IAAs under \$75,000 each Purpose - Rapid Antigen Test kits and associated supplies and equipment	1.9	
CDC -- Rapid Tests Contract: Medical Staffing Network, Inc. Purpose - Lab Workers	0.2	
CDC -- Rapid Tests Contract: Zeptomatrix Corporation Purpose - Establish Repository	0.8	
CDC -- Rapid Tests Contract: Nanogen Inc. Purpose - The advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	4.5	
CDC -- Rapid Tests Contract: Meso Scales Diagnostic LLC Purpose - The advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	0.7	
CDC -- Rapid Tests Contract: Iquum LLC Purpose - The advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	3.8	
CDC -- Rapid Tests Contract: Zeptomatrix Corporation Purpose - Provide unique and quality assured influenza-related reagents and resources in support of accelerated development of clinical diagnostic products for human influenza	1.5	
CDC -- Rapid Tests Contract: Cepheid Purpose - The advanced development and U.S. approval of new or improved in vitro diagnostic products for pandemic and seasonal influenza viruses at Point-of-Care (POC)	2.4	
CDC -- Rapid Tests Contract: Government Scientific Source Purpose - Software and hardware	0.2	
Cumulative Obligations, Rapid Tests	16.9	0.0
<i>Unobligated Balances, Rapid Tests</i>	<i>10.1</i>	<i>40.0</i>
LIBRARY OF REFERENCE STRAINS FUNDING	0.0	13.0
CDC -- Travel & Personnel Costs associated with Library of Reference Strains		1.6
CDC -- Various contracts and IAAs under \$75,000 each Purpose - Technical assistance, consulting, supplies, and equipment supporting Library of Reference Strains activities		1.7
CDC -- Library of Reference Strains Contract: Affymetrix Inc. Purpose - Hyb Oven and FS450		0.1
CDC -- Library of Reference Strains Contract: Qiagen Inc. Purpose - BioRobot		0.1
CDC -- Library of Reference Strains Contract: Bioreliance Corp. Purpose - Contractor will produce master and working banks of mammalian cell lines under cGMP conditions		0.1
Cumulative Obligations, Library of Reference Strains	0.0	3.6
<i>Unobligated Balances, Library of Reference Strains</i>	<i>0.0</i>	<i>9.4</i>
DIAGNOSTIC REAGENT STOCKPILE FUNDING	0.0	13.0
CDC -- Travel & Personnel Costs associated with Diagnostic Reagent Stockpile		0.8
CDC -- Various contracts and IAAs under \$75,000 each Purpose - Technical assistance, consulting, supplies, and equipment supporting Diagnostic Reagent Stockpile		0.6
CDC -- Diagnostic Reagent Stockpile Contract: Biosearch Technologies Purpose - Influenza Primer/Probe Kits		0.2
Cumulative Obligations, Diagnostic Reagent Stockpile	0.0	1.6
<i>Unobligated Balances, Diagnostic Reagent Stockpile</i>	<i>0.0</i>	<i>11.4</i>
REAL-TIME ASSESSMENT FUNDING	0.0	7.0
CDC -- Various grants under \$75,000 each		2.2
CDC -- Real-Time Assessment Grant: Public Health Foundation Enterprises Purpose - Epidemiology and lab capacity for infectious diseases		0.1
CDC -- Real-Time Assessment Grant: Hawaii Department of Health Purpose - Epidemiology and lab capacity for infectious diseases		0.1
CDC -- Real-Time Assessment Grant: Health Research Inc./NYC Dept. of Health Purpose - Epidemiology and lab capacity for infectious diseases		0.1
Cumulative Obligations, Real-Time Assessment	0.0	2.5
<i>Unobligated Balances, Real-Time Assessment</i>	<i>0.0</i>	<i>4.5</i>
DOMESTIC SURVEILLANCE	0.0	10.0
CDC -- Travel & Personnel Costs associated with Domestic Surveillance		1.2
CDC -- Various contracts and IAAs under \$75,000 each Purpose - Technical assistance, consulting, supplies, and equipment supporting Domestic Surveillance activities		0.1
Cumulative Obligations, Domestic Surveillance	0.0	1.3
<i>Unobligated Balances, Domestic Surveillance</i>	<i>0.0</i>	<i>8.7</i>

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
Cumulative Obligations, Other Domestic Activities	108.3	13.3
<i>Unobligated Balances, Other Domestic Activities</i>	<i>29.7</i>	<i>124.7</i>
Risk Communications Funding	33.0	18.0
ASPA -- Message Content Development, Mapping and Evaluation: American Institutes for Research contract	0.7	
Purpose - Conduct regular longitudinal surveys measuring public knowledge, beliefs & perceptions about pandemic flu		
ASPA -- Media Table Top Exercises: Applied Marine Technology Inc. contract	0.8	
Purpose - Plan and conduct six one-day exercises with HHS representatives and major media outlets		
ASPA -- International Communications Planning: World Health Organization (WHO) grant	0.2	
Purpose - Support pandemic communications programs within WHO and in Member States		
ASPA -- HHS-TV Supporting Operations: Hewlett Packard, Sony, Digital Asset Management System, Avid Tech., SCHEDULALL, Prof. Products	0.9	
Purpose - Equipment to upgrade studio's emergency response capabilities including webcast ability, editing, training and testing		
ASPA -- HHS-TV Programming Content and Delivery: Optik Communications contract, Inter-agency Agreement with FDA	2.8	
Purpose - Produce video programming (informational shorts, and Q&A segments)		
ASPA -- Strategic Communications Support: Contract with Ogilvy Public Relations Worldwide	4.9	
Purpose - Plan and conduct public education campaign (Includes \$149,203 administrative fee to GovWorks)		
ASPA -- PandemicFlu.gov Developer Support: Glynn Technologies contract	0.5	
Purpose - Implement content management systems for PandemicFlu.gov		
ASPA -- PandemicFlu.gov Technical Support: Inter-agency Agreement with FDA, Glynn Technologies	0.3	
Purpose - Implement surge capacity and server-back-up systems. Create 1918 Pandemic history site. Domain name registration.		
ASPA -- PandemicFlu.gov Equipment: Percussion license and various contracts under \$75,000	0.2	
Purpose - Licensed content management system to efficiently update content. Equipment to ensure continuity of service during a pandemic		
ASPA -- State Pandemic Summits: Funds provided to IGA	1.3	
Purpose - Plan and execute summits in all states and territories as well as select metropolitan areas		
ASPA -- State Pandemic Summits Travel	0.2	
Purpose - Travel to state summits and related events		
ASPA -- Staff Support for Pandemic Communications: Inter-agency Agreement with CMS; The Washington Center	0.1	
Purpose - Reimbursable detail and internship support to supplement pandemic flu communications staff		
ASPA -- Exercise HHS Press Office Pandemic Response Capabilities: Oak Ridge Institute for Science and Education contract	0.4	
Purpose - Design, develop and implement series of public affairs exercises focused on responding to a pandemic		
CDC -- Travel associated with Risk Communications	0.0	0.1
CDC -- State Pandemic Influenza Summits	1.5	
Purpose - Travel to State Pan Flu Summits and contractor support		
CDC -- Various Message Development Contracts & IAAs under \$75,000 each	0.1	0.04
CDC -- Dept. of Treasury, FedSource IAA: contracts for message development	0.4	
CDC -- Academy for Educational Development contract: promotion of influenza vaccination	0.2	
CDC -- Department of Energy ORISE IAA: message testing	0.8	
CDC -- Science Applications International contract: technical support services	0.6	
CDC -- Society for Public Health Education Grant: build capacity to conduct environmental health education activities	0.0	
CDC -- Public Engagement in Vaccine Access Recommendations: ASTHO and NACCHO		0.7
CDC -- Various Crisis & Emergency Contracts & IAAs under \$75,000 each	0.2	
CDC -- Professional & Scientific Associates Inc. contract: workshops	1.6	
CDC -- National Associates Inc. contract: Public Affairs	0.1	
CDC -- Northrop Grumman Information Technologies contract: technical assistance	0.2	
CDC -- National Public Health Information Coalition Coop Agreement	0.4	
Purpose: assist in the management of the list of invitees and host the networking session of the trainin		
CDC -- Academy for Educational Development contract: promotion of influenza vaccination	0.2	
CDC -- McKing Consulting Corp. contract: Mgmt. consulting for community continuity	0.1	
CDC -- Various Broadcast Communications Contracts & IAAs under \$75,000 each	0.3	
CDC -- CNI Construction LLC. Contract: build broadcast communications capacity needs	1.7	

Activities Funded with FY 2006 Emergency Funding:	FY 2006 December 2005 Supplemental Obligations	FY 2006 June 2006 Supplemental Obligations
CDC -- Various Partner-Professional Communications Channels Contracts & IAAs under \$75,000 each	0.0	
CDC -- McKing Consulting Corp. contract: management consulting	0.2	
CDC -- GSA IAA to Develop and Support Decision System Specific to Influenza	0.8	
CDC -- Gerald Boyd DBA DB Consulting contract: management consulting and technical assistance	0.1	
CDC -- IAA: Dept. of Energy/Oak Ridge Operations	0.1	
Purpose - Staff support to coordinate campaign logistics and provide evaluation and analysis expertise for Pandemic Influenza campaign implementation.		
CDC -- Academy for Educational Development contract: promotion of influenza vaccination	2.7	
CDC -- IAA: Dept. of Energy/Oak Ridge Operations:	0.1	
Purpose - Staff support to coordinate campaign logistics and provide evaluation and analysis expertise for Pandemic Influenza campaign implementation.		
CDC -- Northrop Grumman	0.4	
Purpose - Obtain contract personnel to provide specific oversight of the "emergency" web sites, with an emphasis on communication, content development and user-centered design.		
CDC -- Pearson Government Solutions Inc. contract: pandemic surge assistance	1.5	
CDC -- E.M.T Associates Inc. contract: continuation of quality assurance, assessment, and evaluation	0.1	
CDC -- Phoenix Air Group, Inc. contract: Air charter services and individual mission flights	0.3	
CDC -- Verizon: This contract will create ready state call technology to respond to public during pandemic		0.5
CDC -- Public Awareness Campaign: Academy for Educational Development		0.9
Purpose - This contract will support development of a media buy plan for Nat'l Influenza Vacc. Week		
CDC -- State/Local/Tribal Engagement: Influenza Communication Coordination with ASPA		0.2
Purpose - This IAA with ASPA/HHS supports coordination/tracking		
Cumulative Obligations, Risk Communications	<u>27.7</u>	<u>2.3</u>
<i>Unobligated Balances, Risk Communications</i>	<i>5.3</i>	<i>15.7</i>
Total Cumulative Obligations	2,794.6	172.2
<i>Total Unobligated Balances</i>	<i><u>525.4</u></i>	<i><u>2,097.8</u></i>
Transfer to USAID	<i>0.0</i>	<i><u>30.0</u></i>
Total HHS Pandemic Influenza Supplemental Funding	3,320.0	2,270.0